Longitudinal evaluation of EGFR mutation in plasma for non-small cell lung cancer patients with front-line chemotherapy

被引：0
|
作者：
Hua, B. [1 ]
Zhao, J. [1 ]
Wang, S. H. [1 ]
Yang, L. [1 ]
Duan, J. C. [1 ]
Wu, M. N. [1 ]
Wang, J. [1 ]
机构：
[1] Beijing Tumor Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8099
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer
    Lin, Wei-Chun
    Chiu, Chao-Hua
    Liou, Jia-Ling
    Chen, Yuh-Min
    Perng, Reury-Perng
    Tsai, Chun-Ming
    LUNG CANCER, 2006, 54 (02) : 193 - 199
  • [42] Weekly administration of docetaxel (D) and gemcitabine (G) as front-line chemotherapy of patients with non-small cell lung cancer: An ongoing phase I study.
    Kouroussis, C
    Kakolyris, S
    Mavroudis, D
    Kalbakis, K
    Stathopoulos, G
    Souglakos, J
    Vamvakas, L
    Xenidis, N
    Samonis, G
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 114 - 114
  • [43] Association of plasma EGFR mutations with response to first-line chemotherapy and prognosis in Chinese patients with advanced non-small cell lung cancer
    Wu, M. N.
    Zhao, J.
    Bai, H.
    Zhuo, M. L.
    Wang, S. H.
    Yang, L.
    An, T. T.
    Wang, X.
    Duan, J. C.
    Wang, Y. Y.
    Wang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non-Small Cell Lung Cancer Patients
    Yam, Irene
    Lam, David Chi-Leung
    Chan, Kaimin
    Ho, James Chung-Man
    Ip, Mary
    Lam, Wah-Kit
    Chan, Tai-Kwong
    Chan, Vivian
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : 1131 - 1140
  • [45] ECONOMIC EVALUATION OF GEFITINIB FOR FIRST-LINE TREATMENT OF EGFR MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS IN GREECE
    Fragoulakis, V
    Pallis, A.
    Kourlaba, G.
    Georgoulias, V
    Maniadakis, N.
    VALUE IN HEALTH, 2011, 14 (07) : A454 - A454
  • [46] Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation
    Morinaga, Ryotaro
    Okamoto, Isamu
    Furuta, Kazuyuki
    Kawano, Yukiko
    Sekijima, Masaru
    Dote, Kensaku
    Satou, Takao
    Nishio, Kazuto
    Fukuoka, Masahiro
    Nakagawa, Kazuhiko
    LUNG CANCER, 2007, 58 (03) : 411 - 413
  • [47] KRAS mutation is highly correlated with EGFR alterations in patients with non-small cell lung cancer
    Wang, J. -Y.
    Lin, S. -R.
    EJC SUPPLEMENTS, 2009, 7 (04): : 37 - 37
  • [48] Analysis of the EGFR gene mutation in patients with non-small cell lung cancer in a Chinese population
    Li, Ju-yi
    Liu, Ying
    Deng, Ai-ping
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (08) : 1637 - 1641
  • [49] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR
    Vozniy, Eduard
    Popov, Anatoly
    Galkin, Michail
    Astrakhankina, Tamara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1214 - S1214
  • [50] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
12345